Posted by Michael Wonder on 06 Sep 2024
Travere Therapeutics announces full FDA approval of Filspari (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in IgA nephropathy
5 September 2024 - Conversion to full approval based on results from the PROTECT study, where Filspari delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 head to head trial conducted in IgAN.
Travere Therapeutics today announced that the US FDA has granted full approval to Filspari (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.
